RxDoctor Payments Data

Timothy Dickson, MD

Internal Medicine · Lake Orion, MINPI 1366448896

Payments from drug & device makers

$639in general payments, 2019–2025

Across 44 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$168
  • Sanofi-aventis U.S. LLC$115
  • GSK$63
  • AstraZeneca$62
  • Ironshore Pharmaceuticals Inc.$53
  • Lilly USA, LLC$50
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$639 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$52,804
Medicare patients
153
Services billed
811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$84,086
EliquisApixaban64$80,583
TrulicityDulaglutide47$55,150
JardianceEmpagliflozin32$43,724
FarxigaDapagliflozin Propanediol28$42,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,413
Soliqua 100-33Insulin Glargine/Lixisenatide11$15,861
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,037
Atorvastatin Calcium382$5,446
Breo ElliptaFluticasone/Vilanterol13$5,228
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,089
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,832
Losartan Potassium167$2,490
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,374
Lisinopril209$2,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$168$84,08671 claims
PfizerEliquis$15$80,58364 claims
Lilly USA, LLCTrulicity$50$55,15047 claims
Boehringer IngelheimJardiance$31$43,72432 claims
AstraZenecaFarxiga$62$42,37428 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$63$37,67766 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$115$15,86111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lake Orion

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →